emerging leaders in generics - clarivate...sep 26, 2019 · emerging leaders in generics....
TRANSCRIPT
![Page 1: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/1.jpg)
Emerging Leaders in GenericsSuccessful Strategies for Growth
Brandon Boyd
09.26.2019
![Page 2: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/2.jpg)
Brandon BoydDirector, Strategy & Thought Leadership
2
![Page 3: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/3.jpg)
• Identify successful growth strategies by benchmarking against current leaders
• Reveal the competitive landscape• Explore potential growth accelerators
Objectives
3
![Page 4: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/4.jpg)
EstablishedCompanies with years of experience supplying active ingredients to regulated market.Less EstablishedLess of a track record in supplying to regulated markets, either in terms of years of history or number of products supplied. Still considered as capable of supplying regulated marketsPotential FutureInterest in supplying regulated markets, but with limited or no known performance.LocalSupplying only to their local and other less-regulated markets; do not currently have the capability of passing inspections by regulatory bodies like the US FDA.Big PharmaInnovative companies with at least $1.0B USD in annual R&D expenditures.UnratedCompanies for which Newport has not assigned a rating.
3,200+ companies involved in API productionA highly fragmented manufacturing landscape
4
Source: The Changing Dynamics of Global API Manufacturing, Clarivate Analytics
![Page 5: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/5.jpg)
5
Manufacturers commercially active in international markets Our focus today
582
Potential Future
130
Less Established
215
Established
927
Total Sample
![Page 6: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/6.jpg)
• Horizontal expansion: more products and new markets/territories
• Vertical expansion: more complex, higher margin activities
Growth ModelGeographical
Reach & Business Focus
Global
InternationalMarkets
NeighboringMarkets
DomesticPharma Fine Chemicals
Manufacturers
API Manufacturers
Finished Dose Manufacturers &
Marketers
Super GenericsContract
Research & Manufacturing
Service ProvidersSpecialty Pharma
Innovators
6
![Page 7: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/7.jpg)
Recent changes to the market environmentCan the past still be our guide?
Past conditions
• High volume primary care• Fewer incumbents• Sole exclusivity• Lower barriers to entry• Transactional relationships (in
contract services)
Conditions today
• Low volume specialty• Aggressive new entrants• Shared exclusivity• Facility & GDUFA fees• Strategic/shared accountability
(in contract services)
7
![Page 8: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/8.jpg)
Horizontal Expansion
8
![Page 9: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/9.jpg)
• Benchmarking portfolio sizes across maturity levels
• Regional strategies
Horizontal expansionMore Products
• India and Mainland China focused on achieving scale and breadth• US-, Japan-, EU-based manufacturers more likely to be niche specialists
9Source: Newport, a Cortellis solution
![Page 10: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/10.jpg)
3 5 20
4 20 30
5 33 53
n/a 3 8
• Outliers influence the math and the market
• Gap between India and China is closing
• Top 50% of Established firms bigger than almost all other companies
• 20-API threshold for strategic choices
Portfolio Breadth
TotalMedians
Mainland China
India
USA
12 outliers >120 APIs
10Source: Newport, a Cortellis solution
![Page 11: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/11.jpg)
11
Distribution of Confirmed APIs vs. Active manufacturing filingsGrowth benchmarks in portfolio strategy
• Global / international scale along with larger product portfolios
• Thresholds around 20 and 100 APIs
Source: Newport, a Cortellis solution
![Page 12: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/12.jpg)
12
Distribution of Confirmed APIs vs. Active manufacturing filingsGrowth benchmarks in portfolio strategy
• Global / international scale along with larger product portfolios
• Thresholds around 20 and 100 APIs
• Not fully globalized yet
Source: Newport, a Cortellis solution
![Page 13: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/13.jpg)
13
Distribution of Confirmed APIs vs. Active manufacturing filingsGrowth benchmarks in portfolio strategy
• Global / international scale along with larger product portfolios
• Thresholds around 20 and 100 APIs
• Not fully globalized yet
• Active mostly in less regulated markets• Signs of entry into regulated markets• Potential for additional competitive
pressure
Source: Newport, a Cortellis solution
![Page 14: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/14.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
14Source: Newport, a Cortellis solution
![Page 15: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/15.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
Medicine Cabinet to the World
15Source: Newport, a Cortellis solution
![Page 16: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/16.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
Medicine Cabinet to the World
Specialists & Start-ups
16Source: Newport, a Cortellis solution
![Page 17: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/17.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
Medicine Cabinet to the World
Specialists & Start-ups Diversified
17Source: Newport, a Cortellis solution
![Page 18: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/18.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
Medicine Cabinet to the World
Specialists & Start-ups
Potential Disruptors
Diversified
18Source: Newport, a Cortellis solution
![Page 19: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/19.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsVisualizing the strategic landscape
Medicine Cabinet to the World
Specialists & Start-ups
Potential Disruptors
Diversified
19Source: Newport, a Cortellis solution
![Page 20: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/20.jpg)
Vertical Expansion
20
![Page 21: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/21.jpg)
API OnlyCompanies only associated with API manufacturing.DoseCompanies with a finished dose subsidiary, which can include OTC marketers, generics without U.S. presence and parallel importersUS GenericCompanies that have a generic finished dose presence in the United States.BiotechCompanies associated with biologic products.Small InnovatorCorporations with in-house R&D, but with a small number of innovative products and a regional sales and marketing focus.US SpecialtyGeneric companies that have several branded products in the United States which are unique formulations.
• Two-thirds of Established firms affiliated with finished dose or US Generics activity
– 56% of Less Established
– 33% of Potential Future
Vertical expansionDiversification of capabilities
21Source: Newport, a Cortellis solution
![Page 22: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/22.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsCapabilities expand with maturity
• Specialists and start-ups• Trade-off of more APIs vs. new capabilities
22Source: Newport, a Cortellis solution
![Page 23: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/23.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsCapabilities expand with maturity
• Specialists and start-ups• Trade-off of more APIs vs. new capabilities
• Not fully globalized yet• Potential new competitors in US and/or European
markets
23Source: Newport, a Cortellis solution
![Page 24: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/24.jpg)
Distribution of Confirmed APIs vs. Active manufacturing filingsCapabilities expand with maturity
• Specialists and start-ups• Trade-off of more APIs vs. new capabilities
• Achievement of scale pushes firms to diversify toward higher margin activities
• Not fully globalized yet• Potential new competitors in US market
24Source: Newport, a Cortellis solution
![Page 25: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/25.jpg)
• FDA remains active
• Gap between foreign and domestic visits closing
• Indications of potential new entrants to USA
• 58 Potential Future suppliers have been inspected since 2016 but do not hold active DMFs… yet
– 13 have a regulatory track record in Europe (i.e., active COS)
Competitive InsightsInspections
25Source: Newport, a Cortellis solution
![Page 26: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/26.jpg)
• What will be the effect of stricter regulatory schemes in China and India?
The BIG question
26
![Page 27: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/27.jpg)
Growth Accelerators
27
![Page 28: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/28.jpg)
• High potency active ingredients• Controlled substances• Antibiotics • Peptides, proteins, recombinant formulations• Mono-, polyclonal antibodies
• Dedicated facilities
• Enhanced containment technologies
• Specialized equipment (e.g., lyophilization, micronization)
Growth AcceleratorsNew API types
28
![Page 29: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/29.jpg)
• The Newport Constraint Date (NCD) is a proprietary algorithm that considers patents, market exclusivities and data exclusivities for a specific product in a specific country/territory and estimates the earliest date that a generic could enter the market when the product loses patent or exclusivity protection.
• 300+ unique products potentially face first-time generic competition in just three large markets
• 60 facing loss of exclusivity in more than one of these markets
Growth AcceleratorsUpcoming NCDs
29Source: Newport, a Cortellis solution
US count of products excludes those under active Paragraph Four litigation
![Page 30: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/30.jpg)
Route of Administration of in-sample products with upcoming NCDsIncreasing complexity of new opportunities
166Oral Solids
65Parenterals
(Small molecule)
14Topicals
87Parenterals
(Protein / Biologic)
11Inhalation
8Ophthalmic
30Source: Newport, a Cortellis solution
![Page 31: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/31.jpg)
31
US leads the first worldwide launches followed by Japan and China
US68%
China7%
EU5%
Japan16%
Other4%
• 39 first-in-world launches in the US• 9 launches in Japan, followed by 4 in China• Cambodia had its first first-in-world launch
2018 NME First World launches by country
Source: 2019 CMR Pharmaceutical R&D Factbook
![Page 32: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/32.jpg)
Continuing shift to specialty therapeutics2018 US FDA Novel Drug Approvals
59New Molecular Entities
42Small Molecules
17Biologics
22Orphan Drugs
20Oncology-focused
32Source: US FDA
![Page 33: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/33.jpg)
Continuing shift to specialty therapeutics2018 US FDA Novel Drug Approvals
59New Molecular Entities
42Small Molecules
17Biologics
22Orphan Drugs
20Oncology-focused
Route of Admin. BLA NDA Total
Oral Solid 33 33
Parenteral 16 7 23
Transdermal 1 1
Ophthalmic 1 1
Inhalation 1 1
Capturing value from new products requires diverse, specialized capabilities
33Source: US FDA
![Page 34: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/34.jpg)
• Characteristics of an emerging leader
• Inflection point benchmarks
• International to global in scope• Near or above 20-product benchmark• Diversifying capabilities• Increasingly investing in more complex, higher margin
activities• Pursuing first-time generic opportunities• Able to maintain quality standards
Outlook
34
![Page 35: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/35.jpg)
• Characteristics of an emerging leader
• Inflection point benchmarks
• International to global in scope• Near or above 20-product benchmark• Diversifying capabilities• Increasingly investing in more complex, higher margin
activities• Pursuing first-time generic opportunities• Able to maintain quality standards
• Leadership is not unidimensional
Outlook
35
![Page 36: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/36.jpg)
Questions?
36
![Page 37: Emerging Leaders in Generics - Clarivate...Sep 26, 2019 · Emerging Leaders in Generics. Successful Strategies for Growth. Brandon Boyd. 09.26.2019](https://reader034.vdocuments.mx/reader034/viewer/2022051913/6003bcc7be475a3bb665c6f3/html5/thumbnails/37.jpg)
Going to CPhI Worldwide?
Meet us at Booth 42F33Frankfurt, GermanyNovember 5-7, 2019
37